Six Chinese Cell and Gene Therapy Companies Secure New Funding and Advance Toward IPO

Jan 24, 2024 09:10 CST Updated 09:10

Anlong

Gene Therapy Drug Developer

Recently, several companies in China focusing on the cell and gene therapy (CGT) sector have announced financing progress. This article will share basic information on six of these companies based on publicly available data.

1、Anlong Completes Tens of Millions in A+ Round Financing

January 23, BeijingAnlongAnlong Biotechnology Co., Ltd. (hereinafter referred to as "Anlong Biotech") announced that it successfully completed a multi-million-dollar A+ round of financing in January this year. This round of financing was jointly invested by Taikun Fund and Shunchuang Industry Investment Management Fund. The funds will be used to advance the clinical trials of Anlong Biotech's AAV gene therapy product AL-001 and the research and development of small nucleic acid innovative drugs. Since its establishment, Anlong Biotech has received investments totaling hundreds of millions of yuan from multiple healthcare capital firms. The success of this financing round marks significant progress in Anlong Biotech's research, production, and clinical development of gene therapies, gaining recognition and trust from investors.

Anlong Biotech believes that gene drugs are the next wave in the biopharmaceutical field and has made extensive arrangements in this area. The AAV gene therapy drug AL-001 Ophthalmic Injection, independently developed by the company, obtained the CDE clinical trial approval in April 2023 and successfully completed the first subject dosing in September 2023. The indication for this product isAge-related Macular Degeneration(Wet type). This is the first AAV gene therapy drug in China administered through suprachoroidal space injection (SCS), and also the first internationally to expressAfliberceptGene therapy administered through the suprachoroidal space. The safety of gene drugs is crucial, and administration via the suprachoroidal space is safer and simpler compared to intravitreal and subretinal injections, causing less damage to ocular tissues. Therefore, Anlong's innovative suprachoroidal injection will be one of the core technological advantages in the field of gene therapy. Additionally, Anlong’s ongoing strategic development in the small nucleic acid sector positions it as an ideal partner for traditional pharmaceutical companies. Alongside its collaboration with listed company Kaiyin Technology andSalubrisThe successful cooperation has made its technology platform in the small nucleic acid field increasingly mature, and it is confident in carrying out more collaborations with enterprises both in China and abroad.

2、Hongxin Biotech Completes Pre-A Round Financing of Tens of Millions of Yuan, Accelerating the Creation of an Internationally Leading & China's First Engineered Cell Targeted Delivery Platform

On January 17, Hongxin Biotechnology Co., Ltd. (hereinafter referred to as "Hongxin Biotech") announced the completion of a multi-million yuan Pre-A round of financing. This round of financing was jointly led by Zijin Port Capital and Hongtao Capital, with Shenzhen Angel Direct Investment Fund and Synthesis Capital participating. The funds will be used for the clinical development of the core product HN2201 and the preclinical drug development based on the engineered cell-targeting delivery platform (EnC-LNPs).

Shenzhen MagicRNA Biotechnology Co., Ltd. (MagicRNA), established in December 2021, is a research and development enterprise focusing on nucleic acid drug delivery and innovative therapeutic mRNA drugs. The company's mission is "to deeply cultivate nucleic acid drug delivery and benefit patients with RNA therapy." MagicRNA’s first tumor therapeutic drug, HN2201, has completed preclinical research and received ethical approval for clinical trials from multiple hospitals. It is about to enter the clinical trial stage and received support from Shenzhen's major scientific and technological projects in 2023.

3、Hengrui Yuanzheng Completes Nearly 100 Million Yuan in C3 Round Financing

Recently,Hengrui Yuanzheng(Hangzhou) Biotechnology Co., Ltd. (hereinafter referred to as "Hengrui Yuanzheng") has completed the nearly 100-million-yuan C3 round of financing, with Zijingang Capital continuing its investment. Other follow-up investors includeZhongke ChuangkeAnd other well-known institutions.

Hengrui Yuanzheng was founded in Shanghai in 2015 by Jiangsu Hengrui Pharmaceutical Group and Shenzhen Yuanzheng Cell Medical Technology Co., Ltd. It is an immunotherapy company focusing on solid tumors, ranking among the leading domestic companies and aligning with international standards. The company has developed multiple product pipelines for solid tumor patients, including MASCT, TCR-T, and TCR bispecific antibodies. Currently, the Phase I registrational clinical trial of HRYZ-T101, the first TCR-T product derived from Hengrui Yuanzheng's self-developed ReGET platform for treating cervical cancer, has been initiated. The first patient has successfully received the infusion without any severe adverse reactions. This product is the world’s first TCR-T therapy targeting high-frequency HLA in the Chinese population and is intended to treat human papillomavirus (HPV) Related cervical cancer. At the same time, Hengrui Yuanzheng's multi-antigen autologous immune cell injection (MASCT-I) has launched its second Phase II registration clinical study, combining with first-line chemotherapy to treat advanced soft tissue sarcoma. Previously, MASCT-I monotherapy had completed Phase I clinical research, and the first Phase II registration clinical study is currently underway for maintenance treatment in patients with advanced urothelial carcinoma who benefited from standard first-line chemotherapy.

4、Nuo'en Gene Receives Tens of Millions of Yuan in Strategic Investment

Recently, Chengdu Nuoen Gene Technology Co., Ltd. (hereinafter referred to as "Norgen Gene"") completed a strategic financing round of tens of millions of RMB, led by a fund under Anhong Zhifei Capital, with Tibet Pharmaceutical participating as a follower.

Chengdu Nuoen Gene Technology Co., Ltd. was founded by Mr. Xu Kai, who has engaged in cancer clinical treatment and clinical testing research at the M.D Anderson Cancer Center in the United States for 28 years, and was registered in 2011. After more than ten years of solid research and development, the company has built its own intellectual property system in the two fields of gene therapy and gene testing. It has achieved breakthrough results in gene quantitative detection technology and nucleic acid delivery technology, owning the world's leading dual technology platforms of the original miRFLP-miRNA quantitative detection and nLPX liposome nucleic acid delivery.

5、NulunJie Biotech Completes Pre-A Round Financing Worth Tens of Millions, Focusing on Innovative Gene Therapy for Neural In Situ Transdifferentiation

On January 5, Nulungjie Biomedical Technology (Suzhou) Co., Ltd. (hereinafter referred to as "NylonGene Bio") announced the completion of a multi-million yuan Pre-A round of financing. This round was led by Shanghai Science and Technology Venture Capital Co., Ltd., with participation from Wuhan Baiying, Shanghai Sinan Park Science, and Shanghai Biomedical Public Technology Service Co., Ltd., among other institutions. The founding shareholders of Newron Pharmaceuticals (including the core team) also strategically increased their investment. The funds will be used to further accelerate the company's research and development progress as well as team building efforts.

Since its establishment in December 2021, Nulunjie Biotechnology has successfully completed two rounds of financing from 2022 to 2023 despite the dual challenges of the COVID-19 pandemic and an overall investment funding winter. This fully demonstrates the confidence and support of relevant investment institutions in the development of the in-situ transdifferentiation technology therapeutic field, as well as their affirmation of Nulunjie Biotechnology’s growth potential. Currently, Nulunjie Biotechnology's product pipeline focuses on neurological diseases, particularly developing proprietary gene therapy drugs for blinding eye diseases and difficult-to-treat neurological tumors. The company is rapidly expanding into major neurodegenerative diseases. In the future, there is significant potential to expand into broader areas such as regenerative therapies, cancer treatments, and the emerging anti-aging field.

6、BioRegenerative Medicine Completes Over 100 Million Yuan in Series C Financing

Recently,Biaow Regenerative MedicineCompleted a C-round financing of several hundred million yuan, led by Chang'an Huitong, with investments from Shaanxi Investment Growth, Xi'an Finance, and Yuhua Capital. This round of financing will mainly be used to accelerate the improvement of the regenerative medicine technology platform and the development of regenerative medicine products, as well as to deeply expand the regenerative medicine industry chain.

Regenerative medicine, as a discipline that utilizes the principles of cell, tissue, and organ regeneration to repair and replace damaged tissues, has ushered in a new era of reconstruction, regeneration, manufacturing, and replacement of tissues and organs in the medical industry. Shaanxi BioRegen Biomedical Co., Ltd. is a science and technology innovation biomaterials company driven by regenerative medicine technology. The main businesses of the company and its subsidiaries include implantable regenerative medicine.Class III Medical Devices, organoid skin applications, functional skincare products in regenerative technology, etc. The company's core team is the earliest team in China to engage in regenerative medicine research, having created three world-class scientific research achievements. They were awarded the first National Science and Technology Progress Award in the field of regenerative medicine, and their achievements were twice recognized as one of the top ten advances in China's pharmaceutical biotechnology. They are pioneers in innovative R&D in China’s regenerative medicine.

E.N.D

Previous article recommendations:

Total investment of approximately 2.15 billion yuan, with a construction area exceeding 250,000 square meters! Building a pharmaceutical science and innovation center focusing on cell and gene therapy, innovative medical devices, and digital healthcare.

Central Support for Pudong's High-Level Reform and Opening Up: Comprehensive Optimization of Foreign Investment Access, Scientific Innovation, International Talent, and Government Functions, with Medical and Pharmaceutical Innovation Benefiting in All Aspects!

Illustrated Guide to NK Cell Therapy

Maximum Amount of 5 Billion! Guangzhou Offers Strong Financial Support for Top Biomedical Technologies Such as Cell and Gene Therapy

Hengrui Medicine Subsidiary Submits First Gene Therapy Product

CDE Releases "Non-Clinical Research Technical Guidelines for Human Stem Cell Products"

CDE Releases "Technical Guidelines for Clinical Trials of Gene Therapy Products for Rare Diseases"

Ruijin Hospital Patient with Severe β-Thalassemia Successfully Discharged After BD211 Gene Therapy by Bendao Gene

CRISPR/Cas9 Gene Editing Therapy Receives FDA Approval for Treating β-Thalassemia

The Top Ten Advances in China's Medical and Biotechnology in 2023 Revealed

WuXi Biologics: Sherry Gu to Serve as Chief Technology Officer and Executive Vice President

Review of 40 Global Stem Cell Therapy Companies and Their Technology Pipelines

Further Optimization of Small Nucleic Acid Drugs Can Reduce Production Costs by 60%

A Subsidiary of the CDMO Leader Falls Victim to a Nearly 100 Million Yuan Telecom Fraud, the Largest in A-Share History!

Nuo'en Gene Receives Tens of Millions of Yuan in Strategic Investment

$200 Million in Sales, the First DMD AAV Gene Therapy Drug Exceeds Expectations by a Wide Margin

CAR-T Drug Launches Value-Based Payment Plan, Offering Up to 600,000 Yuan Refund

The Real "Bottleneck" in China's Biomedical Industry

$4.165 Billion! Bo Wang Pharmaceuticals Licenses Multiple RNAi Therapies to Novartis

The First Exosome Anti-Aging Stock Listed, Market Value Exceeds 490 Million Yuan

Direct Delivery of Gene Therapy Drugs into the Brain: Innovative Parkinson's Disease Treatment Meets Primary Endpoint in Clinical Trials

Disclaimer: The content is sourced from the WeChat Official Account "Cell and Gene Therapy Field," the official websites of the aforementioned companies, etc. It aims to share knowledge, and all content is for reference only and does not constitute any advice.